AstraZeneca may not be long for antibiotics; Genmab pockets $10M from J&J;

@FierceBiotech: $GSK cozies up to Five Prime for respiratory R&D. More | Follow @FierceBiotech

@JohnCFierce: Baxter gets FDA OK for hemophilia A drug -- Obizur. News | Follow @JohnCFierce

@DamianFierce:  $AZN's olaparib will trade as Lynparza, which sounds like a nice lady. | Follow @DamianFierce

@EmilyMFierce: Researchers will test blood of Ebola survivors to use as a short-term treatment option. Story | Follow @EmilyMFierce

> AstraZeneca's ($AZN) future in antibiotics may be in jeopardy. Earlier this week, a U.K. blogger speculated that the drugmaker is preparing to exit the field en masse, and the company, speaking to The Wall Street Journal, said it had no immediate plans to shake things up but will "take an opportunity-driven approach in our non-core therapeutic areas," which includes anti-invectives. Story

> Genmab has banked another $10 million milestone in its collaboration with Johnson & Johnson ($JNJ), through which the companies are developing daratumumab, a Phase III treatment for multiple myeloma. Release

Medical Device News

@FierceMedDev: New microscope offers 3D cellular images that are fast, detailed and low toxicity. More | Follow @FierceMedDev

@VarunSaxena2: Bard Q3 earnings up 41% as it focuses on Lutonix launch. Story | Follow @VarunSaxena2

@EmilyWFierce: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

@MichaelGFierce:  Encapsulated #Alzheimers, #Parkinsons-treating growth factors implanted directly in the brain. More from FierceDrugDelivery | Follow @MichaelGFierce

> Apple kicks med tech app developers out of the iCloud. Item

> Edwards profit up 23%, but increased TAVR competition looming. Story

Pharma News

@FiercePharma: Top-read in FiercePharma Thurs: Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it weekly, subscribe. Subscribe | Follow @CarlyHFierce

> Shire poised to succeed as solo act post-AbbVie with solid Q3 earnings. Story

> What does Pfizer's $11B buyback mean for the chances of an AstraZeneca bid? More

> Actavis primed for another deal, or two, or maybe three. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.